Sign In  |  Register  |  About Daly City  |  Contact Us

Daly City, CA
September 01, 2020 1:20pm
7-Day Forecast | Traffic

  • Search Hotels in Daly City

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY: LLY )

831.54 +34.09 (+4.27%)
Official Closing Price Updated: 4:10 PM EST, Nov 8, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2
...
10 11 12 13 14 15 16 17 18
...
99 100 Next >
These 2 Simple ETFs Could Turn $500 a Month Into $1 Million.
Learn how $500 a month can grow into a sizable nest egg. 
Via The Motley Fool
Topics ETFs
Eli Lilly's Obesity Drug Shows a Heart Benefit. Is It Time to Buy?
Recent results from a clinical trial show that treatment with Zepbound significantly reduced patients' risk of heart failure outcomes, including cardiovascular death. 
Via The Motley Fool
3 Unstoppable Stocks to Buy in August
It's not hard to envision how all three of these stocks can deliver exceptional growth. 
Via The Motley Fool
Eli Lilly vs Novo Nordisk: A Recent Study Suggests This Company Has the Best Weight Loss Drug
These healthcare stocks are up more than 400% in the past five years, thanks to their dominance in the anti-obesity market. 
Via The Motley Fool
Is This Decision by Pfizer Bad News for Eli Lilly?
Lilly's revenue gains have helped its stock to roar higher. 
Via The Motley Fool
What's Going On With Eli Lilly Today?
Eli Lilly & Co shares are trading lower Tuesday. Here's what you need to know. 
Via Benzinga
This Is What Whales Are Betting On Eli Lilly and Co
Via Benzinga
Unpacking the Latest Options Trading Trends in Eli Lilly and Co
Via Benzinga
Using Weight Loss Medications Such As Wegovy, Zepbound? Psychologist Warns Of Linked Eating Disorder Risks
Psychologists warn of increased eating disorders linked to popular GLP-1 weight loss drugs like Wegovy and Zepbound. Experts urge better screening and research to address potential risks. 
Via Benzinga
ResMed Earnings Reflect Increased Demand For Sleep Devices, Performance Indicates Positive Dynamics, Opportunities
ResMed reported Q4 2024 revenue of $1.22 billion, driven by strong demand for sleep devices and software services. Gross margin improved significantly due to reduced costs and higher selling prices.... 
Via Benzinga
What's Going On With Eli Lilly and Company Shares Friday
Eli Lilly is anticipated to release earnings on August 8 for the 2024 fiscal year second quarter. 
Via Benzinga
As Diabetes Battle Heats Up, Spotlight Turns To Dexcom, Abbott
Dexcom is taking on bigger rival Abbott Laboratories with a continuous glucose monitor for non insulin users. 
Via Investor's Business Daily
Prediction: This Could Be Amgen's Next Massive Growth Opportunity
The innovative biotech is looking for its next blockbuster. 
Via The Motley Fool
Are Eli Lilly and Novo Nordisk Too Expensive For You? Here Are 4 Other Potential Weight Loss Stocks You May Want to Consider Right Now.
The popularity surrounding weight loss drugs such as Mounjaro and Ozempic has brought Eli Lilly and Novo Nordisk newfound growth. 
Via The Motley Fool
Why Eli Lilly Stock Trounced the Market on Thursday
What's good for Zepbound is good for the company, it seems. 
Via The Motley Fool
What's Going On With HIMS Shares Today?
Hims & Hers Health experienced a significant decline in its stock price on Thursday. Here's what you need to know. 
Via Benzinga
What Are the Hottest Weight Loss Stocks Right Now? 3 Top Picks.
Anti-obesity therapeutics are all the rage and for good reason. Investors seeking to profit should consider these weight loss stocks. 
Via InvestorPlace
8 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Eli Lilly's Popular Weight Loss/Diabetes Drug Tirzepatide Cuts Heart Failure Risk By 38%, Pivotal Phase 3 Study Shows
Eli Lilly's SUMMIT phase 3 trial shows tirzepatide significantly reduces heart failure risk in adults with HFpEF and obesity. Tirzepatide achieved primary and secondary endpoints, including improved... 
Via Benzinga
Pfizer Just Confirmed It's a Dividend Investor's Dream Stock
This big pharma stock gives investors juicy and reliable dividends plus the potential for future growth. 
Via The Motley Fool
Pfizer to Buy a GLP-1 Drugmaker? Here's Why You Shouldn't Count on That Happening
Pfizer's debt load could inhibit the company's ability to take on acquisitions in the near term. 
Via The Motley Fool
The Top 3 Healthcare Stocks to Buy Now: Summer 2024
Investors should consider the long term prospects of the following three healthcare stocks as the U.S. population ages. 
Via InvestorPlace
3 Biotech Stocks That Could Make Your Summer Unforgettable
If you want to do well with biotech stocks, trade the anticipation of news. Here are three stocks to consider. 
Via InvestorPlace
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Unlocking the Next 3 Trillion-Dollar Stock Opportunities
Investors might want to consider the potential of these three superstars poised to become future trillion dollar stocks. 
Via InvestorPlace
1 Weight Loss Pharma Stock to Buy, and 1 to Consider
There's more than one type of worthy opportunity in this space. 
Via The Motley Fool
Healthy Profits: 7 Healthcare Stocks to Build a Lifetime of Wealth
Healthcare stocks offer wealth to investors through a mix of steady performance, growth and income not to be overlooked. 
Via InvestorPlace
DexCom Stock Plunged Over 40% Last Week. Are Eli Lilly's and Novo Nordisk's Drugs to Blame?
DexCom faces several challenges, but GLP-1 drugs aren't big problems for the company right now. 
Via The Motley Fool
Eli Lilly’s $123 Billion Market Value Drop: A Strategic Buying Opportunity?
JPMorgan analyst says Eli Lilly will remain a leader in weight loss drugs. 
Via Talk Markets
3 Overlooked Stocks Poised for a Breakout Very Soon
Discover three overlooked breakout stocks with solid growth prospects, perfect for enhancing your investment portfolio. 
Via InvestorPlace
< Previous 1 2
...
10 11 12 13 14 15 16 17 18
...
99 100 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 DalyCity.com & California Media Partners, LLC. All rights reserved.